Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the impact of chronic hepatitis C (CHC),
and the treatment thereof with peginterferon alpha-2b (PEG) and ribavirin (RBV) according to
standard clinical practice, on the health-related quality of life (HRQL) of a cohort of
participants throughout 72 weeks of follow-up. HRQL was assessed using the 36-Item Short-Form
Health Survey (SF-36) and the Chronic Liver Disease Questionnaire-Hepatitis C Virus
(CLDQ-HCV).